These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15884251)

  • 1. [The effect of transdermal hormone replacement therapy on vasomotor symptoms in perimenopausal women].
    Rozmus-Warcholińska W; Skrzypulec V; Drosdzol A; Kowalczyk R; Nowosielski K; Piela B; Walaszek A
    Wiad Lek; 2004; 57 Suppl 1():254-8. PubMed ID: 15884251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?
    Baerug U; Winge T; Nordland G; Faber-Swensson E; Heldaas K; Norling B; Larsen S; Arce JC
    Climacteric; 1998 Sep; 1(3):219-28. PubMed ID: 11907946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
    Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
    Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes.
    Cunha EP; Azevedo LH; Pompei LM; Strufaldi R; Steiner ML; Ferreira JA; Peixoto S; Fernandes CE
    Climacteric; 2010 Aug; 13(4):362-7. PubMed ID: 20151792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.
    von Holst T; Lang E; Winkler U; Keil D
    Maturitas; 2002 Dec; 43(4):265-75. PubMed ID: 12468135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
    Gambacciani M; Spielmann D; Genazzani AR
    Gynecol Endocrinol; 2005 Aug; 21(2):65-73. PubMed ID: 16294457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy.
    Mattsson LÅ; Ipsen HE; Granqvist CJ; Kokot-Kierepa M;
    Climacteric; 2015 Jun; 18(3):419-25. PubMed ID: 25603163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.
    Panay N; Ylikorkala O; Archer DF; Gut R; Lang E
    Climacteric; 2007 Apr; 10(2):120-31. PubMed ID: 17453860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms.
    Geiger PJ; Eisenlohr-Moul T; Gordon JL; Rubinow DR; Girdler SS
    Menopause; 2019 Nov; 26(11):1318-1323. PubMed ID: 31688579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
    Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
    Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
    Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal hormonal replacement therapy with transdermal progestin every second month.
    Lindgren R; Risberg B; Hammar M; Berg G
    Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms.
    Speroff L; Symons J; Kempfert N; Rowan J;
    Menopause; 2000; 7(6):383-90. PubMed ID: 11127760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.